Judith Aberg
Infectious Disease · New York, NYNPI 1902969645
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $93,772 of the $104,130 with a category attached, or 90.1%. 10 manufacturers reported payments, led by Merck at 43.8% of the total. Reporting peaked in 2019 at $58,046 and has fallen 92.2% since, to $4,504 in 2025. Among infectious disease clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 92 payments — averaging $1131.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$46K
- Viiv Healthcare Company$40K
- GSK$5K
- Janssen Scientific Affairs, LLC$4K
- Theratechnologies Inc.$4K
- Invivyd Inc$2K
- plus $3K from 4 others
Across 452 payments — averaging $32,575 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$4.7M
- Gilead$3.4M
- Regeneron$2.1M
- Janssen Research & Development, LLC$1.8M
- Emergent Biosolutions Inc.$1.3M
- Viiv Healthcare Company$1.1M
- plus $351K from 2 others
What the payments were for
- Consulting fees$93,77290%
- Speaking & faculty fees$3,5003%
- Travel & lodging$5,4205%
- Food & beverage$1,4181%
- Gifts$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 48 | $45,596 |
| Viiv Healthcare Company | 16 | $40,398 |
| GSK | 3 | $5,183 |
| Janssen Scientific Affairs, LLC | 9 | $4,318 |
| Theratechnologies Inc. | 9 | $4,276 |
| Invivyd Inc | 1 | $1,750 |
| Regeneron | 2 | $1,644 |
| Medicure Pharma Inc. | 1 | $500 |
| Pfizer | 2 | $440 |
| Johnson & Johnson | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$104,130 in reported general payments places this provider in the 95th percentile of 799 infectious disease providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 26 | $97,029 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in New York
- Sian JonesNew York$406K
- Antonio UrbinaNew York$373K
- David BekhorNew York$358K
- Genovefa PapanicolaouNew York$209K
- Michelle CespedesNew York$125K
- Donald KaminskyNew York$120K
- Thomas WalshNew York$98K
- Stuart HaberNew York$73K
- Michael GaisaNew York$47K
- Joseph FeczkoNew York$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.